Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lebanon Sci-Tech Weekly.
Press releases published on August 25, 2025
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical- …
CareCloud Closes Medsphere Acquisition, Expanding into the Hospital IT Market
Transformational acquisition extends CareCloud’s reach into inpatient EHR and RCM, bringing affordable solutions to small and mid-sized hospitals nationwide. SOMERSET, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“ …
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, …
Clip Money Inc. Reports Second Quarter 2025 Results
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce its financial results for the …
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a …
CRAFTSMAN+ Achieves Spot #2476 on the 2025 Inc. 5000 List With 171% Revenue Growth
New York, NY, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Inc. has named CRAFTSMAN+ No. 2476 on its 2025 Inc. 5000 list, recognizing the fastest-growing private companies in the U.S. The list celebrates dynamic, independent businesses that are shaping the economy— …
Huntress Celebrates a Decade of Innovation, Growth, and Democratizing Cybersecurity for the World’s Most Vulnerable Businesses
COLUMBIA, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Huntress, the global cybersecurity company on a mission to make enterprise-grade cybersecurity accessible to all businesses, today announced its 10th anniversary. This milestone marks a decade of protecting …
UPCX Signs MOU with Paycle and NTT Digital to Advance Next-Generation Decentralized Payment System
Singapore, Aug. 25, 2025 (GLOBE NEWSWIRE) -- UPCX proudly announces the signing of a Memorandum of Understanding (MOU) with Paycle Inc. (“Paycle”) and NTT Digital, Inc. (“NTT Digital”) to jointly promote research and application of a next-generation …
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of …
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., …
XerpaAI Ignites WebX with the World’s First AI Growth Agent, Ushering in a New Era of Web3 Growth
TOKYO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- XerpaAI made its official debut at WebX Tokyo, Asia’s largest Web3 conference, unveiling the world’s first AI Growth Agent (AGA) — an intelligent, end-to-end solution built to help emerging projects accelerate …
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per …
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on …
Spectral Medical Receives US$3 Million From Vantive
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million …
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company …
Propanc Biopharma Provides Shareholder Update
MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today …
Synaptics To Participate at Upcoming Investor Conferences on Thursday, August 28, 2025 and Thursday, September 4, 2025
SAN JOSE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA) today announced its participation in upcoming investor conferences. Ken Rizvi, CFO, will participate at the Deutsche Bank’s Technology Conference on Thursday, August …
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today …
Climb Bio to Present at Upcoming September 2025 Investor Conferences
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in …